It is Crucell’s goal to improve healthcare throughout the world by fighting infectious diseases. Crucell does this by discovering, researching and developing technologies, vaccines and antibodies, using its own fully integrated infrastructure for in-house development, production and marketing and, where useful or necessary, by establishing partnerships with other companies and organizations.

Headquartered in Leiden, The Netherlands, Crucell currently employs about 1100 people and has subsidiaries in Switzerland, Spain, Sweden, Italy, Korea and the United States. Crucell N.V. is listed on Euronext and NASDAQ (CRXL) and the SWX Swiss Exchange (CRX). At Crucell, we’re bringing innovation to global health.

As the sixth largest vaccine company worldwide, Crucell presents a strong portfolio of products: 

• Quinvaxem^TM ― the fully-liquid vaccine for protection against five important childhood diseases
• Hepavax-Gene^® ― a recombinant hepatitis B vaccine
• MoRu-Viraten^® ― a safe, well-tolerated and effective vaccine for protection against measles and rubella in children, adolescents and adults
• Inflexal^® V ― the virosomal vaccine against influenza
• Epaxal^® ― the only aluminium-free hepatitis A vaccine, without preservatives or antibiotics 
• Vivotif^®  ― the only oral anti-typhoid vaccine
• Dukoral^® ― the only internationally licensed oral vaccine with documented efficacy against diarrhea caused by cholera

Crucell has a broad development pipeline, including vaccines and proteins. Several Crucell products are based on our unique PER.C6^® production technology. Crucell licenses this and other cutting edge technologies to the biopharmaceutical industry. Important partners and licensees are DSM Biologics, sanofi aventis, GSK, Merck & Co. and the US National Institutes of Health (NIH).

Valuable Products 

Innovative Technology

Solid Financial Position

Strong Management